- Home
- WDC vs BMY Comparison
WDC vs BMY Comparison
Compare WDC & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WDC | BMY |
|---|---|---|
| Founded | 1970 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.4B | 123.7B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | WDC | BMY |
|---|---|---|
| Price | $274.86 | $59.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 16 |
| Target Price | ★ $245.09 | $61.81 |
| AVG Volume (30 Days) | 7.0M | ★ 10.0M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | 0.17% | ★ 4.28% |
| EPS Growth | ★ 296.17 | N/A |
| EPS | ★ 7.82 | N/A |
| Revenue | ★ $9,520,000,000.00 | N/A |
| Revenue This Year | $31.83 | N/A |
| Revenue Next Year | $26.32 | N/A |
| P/E Ratio | $37.92 | ★ $17.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.83 | $42.52 |
| 52 Week High | $319.62 | $62.89 |
Technical Indicators
Market Signals| Indicator | WDC | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 51.61 |
| Support Level | $244.20 | $59.23 |
| Resistance Level | $308.67 | $62.47 |
| Average True Range (ATR) | 18.15 | 1.19 |
| MACD | -0.64 | -0.24 |
| Stochastic Oscillator | 33.65 | 65.37 |
Price Performance
Historical ComparisonAbout WDC Western Digital Corporation
Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly, with Western Digital and Seagate being the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.